VetDC Announces New TANOVEA®-CA1 Publication, State of the Art Presentation at VCS 2017 Annual Conference

FORT COLLINS, Colo.–(BUSINESS WIRE)–VetDC, Inc., the leading veterinary cancer therapeutics company, today announced a new TANOVEA®-CA1 (rabacfosadine for injection) publication in Veterinary & Comparative Oncology.  Data from this publication and several new VetDC-sponsored studies was prominently featured in a State … Keep Reading

My Dog has Lymphoma: What Do I Do Now?

My dog has lymphoma. It’s a sentence you never want to hear yourself speaking. Unfortunately, lymphoma is one of the most common cancers in dogs. Many owners will be faced with learning how to deal with that diagnosis and the … Keep Reading

How does TANOVEA®-CA1 work?

TANOVEA®-CA1 is the first lymphoma treatment for dogs that has been conditionally approved by the FDA. Targeting rapidly multiplying lymphoma cells, it mimics a DNA building block, preventing cells from dividing and ultimately causing them to die. The medication is … Keep Reading